London, 7 January 2013 - Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) ("Hikma"), the fast growing multinational pharmaceutical group, today announces the approval of its New Drug Application (NDA) for Phenylephrine HCl Injection, USP, 10mg/mL, 1mL vial by the US Food and Drug Administration (FDA).

Hikma's Phenylephrine is indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation, in such settings as septic shock or anesthesia. This NDA has been approved under Section 505(b)(2) of the US Federal Food Drug and Cosmetic Act and it is the only FDA approved version of Phenylephrine HCl Injection, USP.

Said Darwazah, CEO of Hikma, said, "This approval demonstrates our strong regulatory capabilities and the successful execution of our strategy to develop a more differentiated injectable product portfolio."

According to IMS Health, sales of Phenylephrine Injection in the US market were approximately $14 million for the 12 months ending November 2012.

----- ENDS -----

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal, Investor Relations Director +44 (0)20 7399 2760/ 07776 477 050
Lucinda Henderson, Investor Relations Manager +44 (0)20 7399 2765/ 07818 060 211
FTI Consulting +44 (0)20 7831 3113
Ben Atwell /Julia Phillips/Jonathan Birt/Matthew Cole

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenues of $918.0 million and profit attributable to shareholders of $80.1 million.

Press Release
distributed by